Filing Flows › Health Care › Natures Sunshine Products (NATR)
Natures Sunshine Products (NATR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Natures Sunshine Products (NATR) Q3 2026 earnings results →
Q3 2026 Revenue down 9% year over year to $117M · 2¢ of every $1 of revenue kept as net profit · operating margin 4.5%
Natures Sunshine Products made $117M in Q3 2026 (-9% Y/Y). Operating margin 4.5%, net earnings $1.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $116.6M in Q3 2026, down 9% year over year and roughly flat from the previous quarter.
Gross margin was 72.9%, down 0.4 points from Q3 2025. Operating profit was $5.3M, a 4.5% margin (down 2.5 points year over year). Operating expenses fell 6% while revenue fell 9%. Net earnings were $1.9M, down 65% year over year. The effective tax rate was 64.8%.
Operating cash flow was $10.8M (down 42% year over year), 569% of net earnings. Non-cash charges added back $3.2M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $1.5M left free cash flow of $9.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $117M | -9% | 4.5% | $1.9M | $10.8M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $117M | +2% | 4.7% | $3.5M | $835K |
| Q1 2026 | 10-Q | May 7, 2026 | $123M | +8% | 7.8% | $5.1M | −$1.8M |
| Q4 2025 | 10-K | Mar 10, 2026 | $124M | +5% | 4.3% | $4.1M | $9.9M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $128M | +12% | 7.0% | $5.3M | $18.5M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $115M | +4% | 3.7% | $5.3M | $4.3M |
| Q1 2025 | 10-Q | May 6, 2025 | $113M | +2% | 5.4% | $4.7M | $2.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Natures Sunshine Products
We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation formed in 1976 with our principal place of business in Lehi, Utah. We sell our products to a sales force of independent consultants who use the products themselves or resell them to consumers. We have four business segments (Asia, Europe, North America and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. The geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands.
In its own words, from its 10-K, filed Mar 10, 2026.
Natures Sunshine Products against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -9% against the peers' median +7%. Operating margin: 4.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NATR Natures Sunshine Products | Q3 2026 | $117M | -9% | 4.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Natures Sunshine Products 10-Q on SEC EDGAR · CIK 275053 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns NATR and who is buying
More on NATR
- How Natures Sunshine Products makes money: revenue by segment
- Natures Sunshine Products next earnings date and what analysts expect
- Natures Sunshine Products stock forecast, price target and fair value
- Who owns Natures Sunshine Products stock: holders, funds and Congress trades
- Natures Sunshine Products guidance and outlook
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Natures Sunshine Products guidance history: guided vs reported
- Natures Sunshine Products gross margin by quarter
- Natures Sunshine Products operating margin by quarter
- Natures Sunshine Products net income by quarter
- Natures Sunshine Products free cash flow by quarter
- Natures Sunshine Products capital expenditures by quarter